ArticleNanoscale research letters2016
Suppression of Breast Cancer Cell Migration by Small Interfering RNA Delivered by Polyethylenimine-Functionalized Graphene Oxide.
Article in Nanoscale research letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 59 citations in OpenAlex.
- RNA Delivery Using a Graphene Oxide-Polyethylenimine Hybrid Inhibiting Myotube Differentiation.ACS nanoscience Au · 2025Article
- The mechanical, optical, and thermal properties of graphene influencing its pre-clinical use in treating neurological diseases.Frontiers in neuroscience · 2023Review
- Characteristics of Graphene Oxide for Gene Transfection and Controlled Release in Breast Cancer Cells.International journal of molecular sciences · 2022Review
- Carbon-based Nanomaterials for Delivery of Small RNA Molecules: A Focus on Potential Cancer Treatment Applications.Pharmaceutical nanotechnology · 2022Review
- Opportunities Offered by Graphene Nanoparticles for MicroRNAs Delivery for Amyotrophic Lateral Sclerosis Treatment.Materials (Basel, Switzerland) · 2021Review
- Applications of Pristine and Functionalized Carbon Nanotubes, Graphene, and Graphene Nanoribbons in Biomedicine.Nanomaterials (Basel, Switzerland) · 2021Review
- Graphene-based nanomaterials for breast cancer treatment: promising therapeutic strategies.Journal of nanobiotechnology · 2021Review
- Gene Therapy in Cancer Treatment: Why Go Nano?Pharmaceutics · 2020Review
- Exposure to graphene oxide sheets alters the expression of reference genes used for real-time RT-qPCR normalization.Scientific reports · 2019Article
- Promise of chemokine network-targeted nanoparticles in combination nucleic acid therapies of metastatic cancer.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019Review
- Magnetic chitosan/graphene oxide composite loaded with novel photosensitizer for enhanced photodynamic therapy.RSC advances · 2018Article
- Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.International journal of molecular sciences · 2017Review
- Graphene materials as 2D non-viral gene transfer vector platforms.Gene therapy · 2017Review
- Multifunctionalization of graphene and graphene oxide for controlled release and targeted delivery of anticancer drugs.American journal of translational research · 2017Review
- Efficient delivery of Notch1 siRNA to SKOV3 cells by cationic cholesterol derivative-based liposome.International journal of nanomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The carbon-based nanomaterial graphene can be chemically modified to associate with various molecules such as chemicals and biomolecules and developed as novel carriers for drug and gene delivery. In this study, a nonviral gene transfection reagent was produced by functionalizing graphene oxide (GO) with a polycationic polymer, polyethylenimine (PEI), to increase the biocompatibility of GO and to transfect small interfering RNA (siRNA) against C-X-C chemokine receptor type 4 (CXCR4), a biomarker associated with cancer metastasis, into invasive breast cancer cells. PEI-functionalized GO (PEI-GO) was a homogeneous aqueous solution that remained in suspension during storage at 4 °C for at least 6 months. The particle size of PEI-GO was 172 ± 4.58 and 188 ± 5.00 nm at 4 and 25 °C, respectively, and increased slightly to 262 ± 17.6 nm at 37 °C, but remained unaltered with time. Binding affinity of PEI-GO toward siRNA was assessed by electrophoretic mobility shift assay (EMSA), in which PEI-GO and siRNA were completely associated at a PEI-GO:siRNA weight ratio of 2:1 and above. The invasive breast cancer cell line, MDA-MB-231, was transfected with PEI-GO in complex with siRNAs against CXCR4 (siCXCR4). Suppression of the mRNA and protein expression of CXCR4 by the PEI-GO/siCXCR4 complex was confirmed by real-time PCR and western blot analysis. In addition, the metastatic potential of MDA-MB-231 cells was attenuated by the PEI-GO/siCXCR4 complex as demonstrated in wound healing assay. Our results suggest that PEI-GO is effective in the delivery of siRNA and may contribute to targeted gene therapy to suppress cancer metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.